ロード中...
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
BACKGROUND: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. METHODS: We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa inhibitor. The patients received a bolus of andexa...
保存先:
| 出版年: | N Engl J Med |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6699827/ https://ncbi.nlm.nih.gov/pubmed/30730782 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1814051 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|